+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      L-Carnitine Addition to Dialysis Fluid

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          L-Carnitine has been reported to have beneficial effects in the reduction of serum triglycerides and increases high-density lipoprotein cholesterol in hemodialysis patients. The published reports are, however, equivocal. Paradoxical increases in serum triglycerides following intravenous administration of L-carnitine have been observed. It has been suggested that the paradoxical rise in triglycerides may result from the high doses used and intravenous administration, both of which may cause abnormally high tissue concentrations. In the present study 22 hemodialysis patients were selected. All patients had been treated intravenously with 2 g of L-carnitine administered at the end of dialysis for a minimum of 12 months. Treatment with L-carnitine was then discontinued during a 4-month washout period. The patients were then divided into two equal subgroups and placed on L-carnitine therapy (1 g i.v.) at the end of dialysis for 1 month. Thereafter, L-carnitine was added to the dialysate (2 g in group 1, 4 g in group 2) for 3 months. Serum and muscle carnitine levels were determined throughout the study as were lipid parameters, serum chemistry, and hematoiogy. Muscle biopsies obtained at baseline revealed supranormal levels of carnitine which decreased to normal levels following the 4-month washout period. When therapy with L-carnitine was resumed, intravenous administration or in dialysate, the muscle carnitine levels remained within the normal range. Similarly, serum carnitine was markedly elevated at baseline and decreased to normal during the washout period. When L-carnitine was added to the dialysate, total carnitine was observed to significantly increase in the group receiving 4 g. No other significant differences in serum carnitine were observed. A progressive worsening of the lipid profile as evidenced by an increase in triglycerides, and a decrease in high-density lipoprotein cholesterol was observed in patients during the 4-month washout period. Treatment with L-carnitine (intravenously and in the dialysate) decreased triglyceride levels and increased high-density lipoprotein cholesterol. No significant differences were observed between the 2-gram and 4-gram doses of L-carnitine added to the dialysate. It is concluded that the therapeutic objectives in the supplementation of hemodialysis patients with L-carnitine may be best achieved with short-term intravenous administration of L-carnitine followed by long-term administration through the dialysate.

          Related collections

          Author and article information

          S. Karger AG
          09 December 2008
          : 51
          : 2
          : 237-242
          aDepartment of Nephrology and Dialysis, Ospedale Mauriziano Umberto I, Turin; bLaboratorio Analisi, Ospedale L. Spallanzani, Rome; clstituto Neurologico C. Besta, Milan, Italy; dSigma-Tau Inc., Holmdel, N.J., USA
          185292 Nephron 1989;51:237–242
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper

          Cardiovascular Medicine, Nephrology

          Hemodialysis fluid, Carnitine, Muscle biopsy, Hemodialysis, Uremia


          Comment on this article